title: Helicobacter pylori of the remnant stomach and its eradication.
abstract: OBJECTIVE
  Many authors have reported that Helicobacter pylori (H. pylori) is one of the major causes of gastritis and peptic ulcer. This study was conducted to evaluate the incidence of H. pylori infection and the curative effects of amoxicillin and omeprazole on H. pylori in the remnant stomach.
  
  
  METHODS
  Biopsy specimens were obtained from 70 patients who underwent gastrectomy for gastric cancer. H. pylori was subsequently diagnosed by CLO test and culture of H. pylori. Gastritis was assessed by the scoring of four characteristic pathological parameters. Patients with positive H. pylori were eligible for the eradication study. Amoxicillin, 750 mg per day for 2 weeks, and omeprazole, 20 mg per day for 8 weeks, were administered to them. Endoscopic reexamination was performed 12 weeks after the initiation of treatment.
  
  
  RESULTS
  The overall positive rate of H. pylori was 37.1%; 39.6% in Billroth I reconstruction, 0% in Billroth II reconstruction, and 55.6% in pylorus preserving gastrectomy, respectively. The positive H. pylori rate of Billroth II reconstruction was significantly low. However, there was no association of positive rate of H. pylori with time. There was no significant difference of gastritis scores between H. pylori infected patients and non-infected patients. The eradication rate was 70.0%.
  
  
  CONCLUSIONS
  H. pylori was present in 37.1% of patients who underwent gastrectomy. Gastritis was not significantly severe in H. pylori infected patients. The treatment with amoxicillin and omeprazole was effective for these patients.
authors.affiliation: First Department of Surgery, Yokohama City University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Rino
authors.forename: T
authors.initials: T
authors.lastname: Imada
authors.forename: M
authors.initials: M
authors.lastname: Shiozawa
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Fukuzawa
authors.forename: K
authors.initials: K
authors.lastname: Hasuo
authors.forename: A
authors.initials: A
authors.lastname: Nagano
authors.forename: J
authors.initials: J
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Hatori
authors.forename: T
authors.initials: T
authors.lastname: Amano
authors.forename: J
authors.initials: J
authors.lastname: Kondo
mesh_terms: D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001706:Biopsy; D004359:Drug Therapy, Combination; D005260:Female; D005743:Gastrectomy; D018530:Gastric Stump / Q000473:pathology*; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000382:microbiology / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D000658:Amoxicillin; D009853:Omeprazole